Share This Article:

Liver Cancer: Zheng Classification of Qi Stagnation and Blood Stasis

Abstract Full-Text HTML Download Download as PDF (Size:165KB) PP. 75-82
DOI: 10.4236/pp.2014.51012    4,792 Downloads   6,380 Views   Citations

ABSTRACT

There is a long history of using traditional Chinese medicine in the treatment of liver cancer and other malignnancies. The classification of Qi stagnation and blood stasis (QSBS) is the most common Zheng in liver cancer. This Zheng is frequently encountered in liver cancers falling into the pathological category of massive type. QSBS is the principal mechanism for a tumor to develop. Liver cancer with QSBS Zheng has characteristic clinical manifestations. Evidence from ex vivo, in vivo and clinical studies has been reported for the identification and management of liver cancer with QSBS Zheng. This article reviews evidence-based study advances of QSBS Zheng, the most common Zheng encountered in liver cancer.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Y. Guan and Q. He, "Liver Cancer: Zheng Classification of Qi Stagnation and Blood Stasis," Pharmacology & Pharmacy, Vol. 5 No. 1, 2014, pp. 75-82. doi: 10.4236/pp.2014.51012.

References

[1] J. F. Bridges, L. Dong, G. Gallego, B. M. Blauvelt, S. M. Joy and T. M. Pawlik, “Prioritizing Strategies for Comprehensive Liver Cancer Control in Asia: A Conjoint Analysis,” BMC Health Services Research, Vol. 12, No. 1, 2012, p. 376.
http://dx.doi.org/10.1186/1472-6963-12-376
[2] T. Livraghi, H. Makisalo and P. D. Line, “Treatment Options in Hepatocellular Carcinoma Today,” Scandinavian Journal of Surgery, Vol. 100, No. 1, 2011, pp. 22-29.
[3] A. C. Chan, R. T. Poon, T. T. Cheung, et al., “Survival Analysis of Re-Resection versus Radiofrequency Ablation for Intrahepatic Recurrence after Hepatectomy for Hepatocellular Carcinoma,” World Journal of Surgery, Vol. 36, No. 1, 2012, pp. 151-156.
http://dx.doi.org/10.1007/s00268-011-1323-0
[4] Q. Gao, Y. Shi, X. Wang, J. Zhou, S. Qiu and J. Fan, “Translational Medicine in Hepatocellular Carcinoma,” Frontiers of Medicine, Vol. 6, No. 2, 2012, pp. 122-133.
http://dx.doi.org/10.1007/s11684-012-0193-7
[5] R. Wong and C. Frenette, “Updates in the Management of Hepatocellular Carcinoma,” Gastroenterology and Hepatology, Vol. 7, No. 1, 2011, pp. 16-24.
[6] J. M. Luk, X. Wang, P. Liu, et al., “Traditional Chinese Herbal Medicines for Treatment of Liver Fibrosis and Cancer: From Laboratory Discovery to Clinical Evaluation,” Liver International, Vol. 27, No. 7, 2007, pp. 879-890. http://dx.doi.org/10.1111/j.1478-3231.2007.01527.x
[7] Z. Sun, S. T. Liang, X. F. Zhai, et al., “A Traditional Chinese Herbal Medicine Compound Preparation versus Interventional Therapy after Resection of Small Hepatocellular Carcinoma: 22-Year Follow-Up,” Journal of Traditional Chinese Medicine, Vol. 32, No. 2, 2012, pp. 156-163.
http://dx.doi.org/10.1016/S0254-6272(13)60005-9
[8] X. Liu and N. Li, “Regularity Analysis on Clinical Treatment in Primary Liver Cancer by Traditional Chinese Medicine,” China Journal of Chinese Materia Medica, Vol. 37, No. 9, 2012, pp. 1327-1331.
[9] Z. Y. Xu, “Evidence-Based Medicine and Treatment of Lung Cancer,” Journal of Chinese Integrative Medicine, Vol. 1, No. 2, 2003, pp. 151-154.
http://dx.doi.org/10.3736/jcim20030221
[10] Q. H. Fu, J. Pei, J. R. Hui and Y. Song, “Studies on Dynamic Changes in Traditional Chinese Medicine Syndrome Patterns for Stroke Using Data-Driven and Model-Driven Approaches: A Review,” Journal of Chinese Integrative Medicine, Vol. 9, No. 12, 2011, pp. 1292-1300. http://dx.doi.org/10.3736/jcim20111203
[11] K. Qu, T. F. Wang, Y. Zhao, et al., “Common Syndrome Factors of Traditional Chinese Medicine in Chronic Renal Failure Based on the Questionnaire Investigation among Experts,” Journal of Chinese Integrative Medicine, Vol. 8, No. 12, 2010, pp. 1147-1152.
http://dx.doi.org/10.3736/jcim20101206
[12] C. Chen, Y. M. Meng, P. Zhang, et al., “Diagnosis and Treatment Rule of Traditional Chinese Medicine for Syndrome Factors of Chronic Congestive Heart Failure: A Study Based on Shannon Entropy Method,” Journal of Chinese Integrative Medicine, Vol. 8, No. 11, 2010, pp. 1080-1084. http://dx.doi.org/10.3736/jcim20101113
[13] T. F. Wang, C. F. Du, Q. G. Wang, et al., “A Perspective of Developing Syndrome Diagnostic Criteria Based on Syndrome Factors and Combination of Disease in Modern Medicine System and Syndrome in Traditional Chinese Medicine System,” Journal of Chinese Integrative Medicine, Vol. 7, No. 10, 2009, pp. 901-906.
http://dx.doi.org/10.3736/jcim20091001
[14] T. F. Wang, J. J. Wang, X. L. Xue, et al., “Distribution Characteristics of Traditional Chinese Medicine Syndromes and Their Elements in People with Subhealth Fatigue,” Journal of Chinese Integrative Medicine, Vol. 8, No. 3, 2010, pp. 220-223.
http://dx.doi.org/10.3736/jcim20100304
[15] Y. H. Zhang, X. Qin and J. Xu, “Analysis of Chinese Medical Syndrome Features of Patients with Primary Liver Cancer before and after Transcatheter Arterial Chemoembolization,” Chinese Journal of Integrated Traditional and Western Medicine, Vol. 32, No. 9, 2012, pp. 1171-1174.
[16] Q. Liu, X. Q. Yue, W. Z. Deng and R. Z. Ren, “Quantitative Study on Tongue Color in Primary Liver Cancer Patients by Analysis System for Comprehensive Information of Tongue Diagnosis,” Journal of Chinese Integrative Medicine, Vol. 1, No. 3, 2003, pp. 180-183.
http://dx.doi.org/10.3736/jcim20030310
[17] D. Z. Sun, L. Liu, J. P. Jiao, P. K. Wei, L. D. Jiang and L. Xu, “Syndrome Characteristics of Traditional Chinese Medicine: Summary of a Clinical Survey in 767 Patients with Gastric Cancer,” Journal of Chinese Integrative Medicine, Vol. 8, No. 4, 2010, pp. 332-340.
http://dx.doi.org/10.3736/jcim20100406
[18] C. W. Cheng, A. O. Kwok, Z. X. Bian and D. M. Tse, “The Quintessence of Traditional Chinese Medicine: Syndrome and Its Distribution among Advanced Cancer Patients with Constipation,” Evidence-Based Complementary and Alternative Medicine, Vol. 2012, 2012, Article ID: 739642. http://dx.doi.org/10.1155/2012/739642
[19] T. Wang, C. Jia, Y. Chen, X. Li and J. Cheng, “Analysis on Establishment and Affecting Factors of Qi Stagnation and Blood Stasis Rat Model,” China Journal of Chinese Materia Medica, Vol. 37, No. 11, 2012, pp. 1629-1633.
[20] Y. Liu, P. Liu, R. Dai, et al., “Analysis of Plasma Proteome from Cases of the Different Traditional Chinese Medicine Syndromes in Patients with Chronic Hepatitis B,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 59, 2012, pp. 173-178.
http://dx.doi.org/10.1016/j.jpba.2011.10.002
[21] H. F. Wei, T. Liu, L. J. Xing, P. Y. Zheng and G. Ji, “Distribution Pattern of Traditional Chinese Medicine Syndromes in 793 Patients with Fatty Liver Disease,” Journal of Chinese Integrative Medicine, Vol. 7, No. 5, 2009, pp. 411-417.
http://dx.doi.org/10.3736/jcim20090503
[22] K. Z. Liu, “Relation between Traditional Chinese Medicine Differentiation of Syndromes and HBV Antigen, HBV DNA in Serum and Liver Tissues and Pathological Changes in Chronic Hepatitis B,” Chinese Journal of Integrated Traditional and Western Medicine, Vol. 12, No. 1, 1992, pp. 11-13.
[23] H. Uzuner, R. Bauer, T. P. Fan, et al., “Traditional Chinese Medicine Research in the Post-Genomic Era: Good Practice, Priorities, Challenges and Opportunities,” Journal of Ethnopharmacology, Vol. 140, No. 3, 2012, pp. 458-468. http://dx.doi.org/10.1016/j.jep.2012.02.028
[24] X. P. Wang, W. F. Zhang, H. Y. Huang and M. Preter, “Neurology in the People’s Republic of China—An Update,” European Neurology, Vol. 64, No. 6, 2010, pp. 320-324. http://dx.doi.org/10.1159/000321648
[25] S. Xutian, D. Cao, J. Wozniak, J. Junion and J. Boisvert, “Comprehension of the Unique Characteristics of Traditional Chinese Medicine,” The American Journal of Chinese Medicine, Vol. 40, No. 2, 2012, pp. 231-244.
http://dx.doi.org/10.1142/S0192415X12500188
[26] C. Q. Ling, Q. Liu, D. T. Li, et al., “Study of a Qualitative Diagnostic Criterion for Basic Syndromes of Traditional Chinese Medicine in Patients with Primary Liver Cancer,” Journal of Chinese Integrative Medicine, Vol. 3, No. 2, 2005, pp. 95-98.
http://dx.doi.org/10.3736/jcim20050204
[27] B. Jiang, X. Liang, Y. Chen, et al., “Integrating NextGeneration Sequencing and Traditional Tongue Diagnosis to Determine Tonguecoating Microbiome,” Scientific Reports, Vol. 2, No. 936, 2012.
[28] J. H. Qin and B. Liu, “Tongue Tip Microcirculation in Patients with Different Symptoms,” Chinese Journal of Integrated Traditional and Western Medicine, Vol. 10, No. 10, 1990, pp. 606-608.
[29] T. S. Chen and P. S. Chen, “The Liver in Traditional Chinese Medicine,” Journal of Gastroenterology and Hepatology, Vol. 13, No. 4, 1998, pp. 437-442.
http://dx.doi.org/10.1111/j.1440-1746.1998.tb00662.x
[30] D. T. Li, C. Q. Ling, Q. B. Lang ,et al., “Construction of a Therapeutic Effect Evaluation System for Patients with Primary Liver Cancer Based on Syndrome Differentiation in Traditional Chinese Medicine,” Journal of Chinese Integrative Medicine, Vol. 5, No. 1, 2007, pp. 15-22.
http://dx.doi.org/10.3736/jcim20070104
[31] G. Xiong, C. Virasakdi, A. Geater, Y. Zhang, M. Li and S. Lerkiatbundit, “Factor Analysis on Symptoms and Signs of Chronic Low-Back Pain Based on Traditional Chinese Medicine Theory,” Journal of Alternative and Complementary Medicine, Vol. 17, No. 1, 2011, pp. 51-55.
[32] Q. Zhang, P. Liu, H. F. Cheng, et al., “Clinical Investigation on Characteristics of Traditional Chinese Medical Syndrome of Hepatocirrhosis,” Journal of Chinese Integrative Medicine, Vol. 1, No. 2, 2003, pp. 108-112.
http://dx.doi.org/10.3736/jcim20030207
[33] F. G. Hou, Y. Cen, J. Guan, L. Y. Zhu and X. L. Yin, “Quantified Diagnositic Standard for Large Intestinal Cancer of Spleen Qi Deficiency Syndrome,” Journal of Chinese Integrative Medicine, Vol. 7, No. 9, 2009, pp. 814-818. http://dx.doi.org/10.3736/jcim20090903
[34] Y. Feng, Z. Wu, X. Zhou, Z. Zhou and W. Fan, “Knowledge Discovery in Traditional Chinese Medicine: State of the Art and Perspectives,” Artificial Intelligence in Medicine, Vol. 38, No. 3, 2006, pp. 219-236.
http://dx.doi.org/10.1016/j.artmed.2006.07.005
[35] R. Q. Chen, C. M. Wong, K. J. Cao and T. H. Lam, “An Evidence-Based Validation of Traditional Chinese Medicine Syndromes,” Complementary Therapies in Medicine, Vol. 18, No. 5, 2010, pp. 199-205.
http://dx.doi.org/10.1016/j.ctim.2010.05.036
[36] R. Q. Chen, C. M. Wong and T. H. Lam, “Construction of a Traditional Chinese Medicine Syndrome-Specific Outcome Measure: The Kidney Deficiency Syndrome Questionnaire (KDSQ),” BMC Complementary and Alternative Medicine, Vol. 6, No. 12, 2012, p. 73.
http://dx.doi.org/10.1186/1472-6882-12-73
[37] L. Hu, S. X. Lao, Z. Y. Kuang and M. Cheng, “Thoughts on Pathogenesis of Helicobacter Pylori Related Gastrosis with Splenogastric Hygropyrexia Syndrome,” Journal of Chinese Integrative Medicine, Vol. 6, No. 6, 2008, pp. 565-568. http://dx.doi.org/10.3736/jcim20080604
[38] W. Liu, X. Y. Liu and H. B. Zhang, “Exploration into Relationship between TCM Syndrome Type and Laboratory Indexes in Patients with Systemic Lupus Erythematosus,” Chinese Journal of Integrated Traditional and Western Medicine, Vol. 28, No. 2, 2008, pp. 115-117.
[39] G. J. Dobos, B. Kirschbaum and K. E. Choi, “The Western Model of Integrative Oncology: The Contribution of Chinese Medicine,” Chinese Journal of Integrative Medicine, Vol. 18, No. 9, 2012, pp. 643-651.
http://dx.doi.org/10.1007/s11655-012-1200-1
[40] J. J. Lin, C. N. Jin, M. L. Zheng, X. N. Ouyang, J. X. Zeng and X. H. Dai, “Clinical Study on Treatment of Primary Hepatocellular Carcinoma by Shenqi Mixture Combined with Microwave Coagulation,” Chinese Journal of Integrative Medicine, Vol. 11, No. 2, 2005, pp. 104-110.
http://dx.doi.org/10.1007/BF02836465
[41] P. Song, R. G. Tobe, Y. Inagaki, N. Kokudo, K. Hasegawa, Y. Sugawara and W. Tang, “The Management of Hepatocellular Carcinoma around the World: A Comparison of Guidelines from 2001 to 2011,” Liver International, Vol. 32, No. 7, 2012, pp. 1053-1063.
http://dx.doi.org/10.1111/j.1478-3231.2012.02792.x
[42] Y. Yu, Q. Lang, Z. Chen, B. Li, C. Q. Yu, D. Z. Zhu, X. F. Zhai and C. Q. Ling, “The Efficacy for Unresectable Hepatocellular Carcinoma May Be Improved by Transcatheter Arterial Chemoembolization in Combination with a Traditional Chinese Herbal Medicine Formula: A Retrospective Study,” Cancer, Vol. 115, No. 22, 2009, pp. 5132-5138. http://dx.doi.org/10.1002/cncr.24567
[43] J. L. Raoul, B. Sangro, A. Forner, V. Mazzaferro, F. Piscaglia, L. Bolondi and R. Lencioni, “Evolving Strategies for the Management of Intermediate-Stage Hepatocellular Carcinoma: Available Evidence and Expert Opinion on the Use of Transarterial Chemoembolization,” Cancer Treatment Reviews, Vol. 37, No. 3, 2011, pp. 212-220.
http://dx.doi.org/10.1016/j.ctrv.2010.07.006
[44] M. B. Meng, Y. L. Cui, Y. S. Guan, Z. Ying, M. H. Zheng, C. K. Yuan and R. M. Zhang, “Traditional Chinese Medicine plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma,” Journal of Alternative and Complementary Medicine, Vol. 14, No. 8, 2008, pp. 1027-1042.
http://dx.doi.org/10.1089/acm.2008.0060
[45] P. Wu, J. J. Dugoua, O. Eyawo and E. J. Mills, “Traditional Chinese Medicines in the Treatment of Hepatocellular Cancers: A Systematic Review and Meta-Analysis,” Journal of Experimental & Clinical Cancer Research, Vol. 28, 2009, p. 112.
http://dx.doi.org/10.1186/1756-9966-28-112
[46] J. X. Yang, I. Fichtner, M. Becker, M. Lemm and X. M. Wang, “Anti-Proliferative Efficacy of Icariin on HepG2 Hepatoma and Its Possible Mechanism of Action,” American Journal of Chinese Medicine, Vol. 37, No. 6, 2009, pp. 1153-1165.
http://dx.doi.org/10.1142/S0192415X09007569
[47] D. Guan, Z. Fang, H. Lu and H. Li, “Preliminary Investigation on Regulating Effects of Different TCM Treatments on Transcription of the Correlated Genes of Liver Cancer in Rats,” Journal of Traditional Chinese Medicine, Vol. 23, No. 1, 2003, pp. 62-66.
[48] Z. Chen, L. M. Liu and Y. B. He, “Correlation between TXB2, 6-Keto-PGF1α and Liver Metastasis in Rats Model with Blood Stasis,” Journal of Chinese Integrative Medicine, Vol. 1, No. 3, 2003, pp. 199-201.
http://dx.doi.org/10.3736/jcim20030316
[49] J. S. You, H. F. Huang and D. M. Hau, “Effects of Xuefu Zhuyu Tang and Mitomycin C on Liver Tumors in Mice,” Chang Gung Medical Journal, Vol. 26, No. 6, 2003, pp. 417-424.
[50] T. Chen, D. Li, Y. L. Fu and W. Hu, “Screening of QHF Formula for Effective Ingredients from Chinese Herbs and Its Anti-Hepatic Cell Cancer Effect in Combination with Chemotherapy,” Chinese Medical Journal, Vol. 121, No. 4, 2008, pp. 363-368.
[51] J. Y. Chen, H. L. Chen, J. C. Cheng, H. J. Lin, Y. T. Tung, C. F. Lin and C. M. Chen, “A Chinese Herbal Medicine, Gexia-Zhuyu Tang (GZT), Prevents DimethylnitrosamineInduced Liver Fibrosis through Inhibition of Hepatic Stellate Cells Proliferation,” Journal of Ethnopharmacology, Vol. 142, No. 3, 2012, pp. 811-818.
http://dx.doi.org/10.1016/j.jep.2012.06.005
[52] S. Huang, S. J. Chang, M. Yang, J. J. Chen and W. H. Chang, “Nanoscale Hepatoprotective Herbal Decoction Attenuates Hepatic Stellate Cell Activity and ChloroformInduced Liver Damage in Mice,” International Journal of Nanomedicine, Vol. 6, 2011, pp. 1365-1371.
http://dx.doi.org/10.2147/IJN.S19503
[53] W. Y. Cheng, S. L. Wu, C. Y. Hsiang, et al., “Relationship Between San-Huang-Xie-Xin-Tang and Its Herbal Components on the Gene Expression Profiles in HepG2 Cells,” American Journal of Chinese Medicine, Vol. 36, No. 4, 2008, pp. 783-797.
http://dx.doi.org/10.1142/S0192415X08006235
[54] Z. Sun, Y. H. Su and X. Q. Yue, “Professor Ling Changquan’s Experience in Treating Primary Liver Cancer: An Analysis of Herbal Medication,” Journal of Chinese Integrative Medicine, Vol. 6, No. 12, 2008, pp. 1221-1225.
http://dx.doi.org/10.3736/jcim20081203
[55] Z. Zhang, H. F. Que, Y. Y. Zhu, Y. F. Wang, X. D. Liu and P. Y. Zheng, “Effects of Chinese Herbs for Replenishing Qi and Resolving Stagnation on Transforming Growth Factor-Beta1 of Skin Ulcers in Rats with Diabetes,” Journal of Chinese Integrative Medicine, Vol. 5, No. 4, 2007, pp. 416-420. http://dx.doi.org/10.3736/jcim20070411
[56] W. Cao and A. G. Zhao, “Prescription Rules of Chinese Herbal Medicines in Treatment of Gastric Cancer,” Journal of Chinese Integrative Medicine, Vol. 7, No. 1, 2009, pp. 1-8. http://dx.doi.org/10.3736/jcim20090101
[57] Z. Y. Gao, H. Xu, D. Z. Shi, C. Wen and B. Y. Liu, “Analysis on Outcome of 5284 Patients with Coronary Artery Disease: The Role of Integrative Medicine,” Journal of Ethnopharmacology, Vol. 141, No. 2, 2012, pp. 578-583.
http://dx.doi.org/10.1016/j.jep.2011.08.071
[58] Y. Xiao, F. Q. Yang, S. P. Li, G. Hu, S. M. Lee and Y. T. Wang, “Essential Oil of Curcuma wenyujin Induces Apoptosis in Human Hepatoma Cells,” World Journal of Gastroenterology, Vol. 14, No. 27, 2008, pp. 4309-4918.
http://dx.doi.org/10.3748/wjg.14.4309
[59] Y. L. Huang, “Cupping-Bloodletting Therapy of Saudi Arabia and Its Clinical Application,” Chinese Acupuncture & Moxibustion, Vol. 28, No. 5, 2008, pp. 375-377.
[60] K. Vanderploeg and X. Yi, “Acupuncture in Modern Society,” Journal of Acupuncture and Meridian Studies, Vol. 2, No. 1, 2009, pp. 26-33.
[61] L. Y. Chen and S. Y. Yan, “Embodiment of ‘Harmony’ in the Concept of Well-Being of China,” Chinese Journal of Medical History, Vol. 40, No. 5, 2010, pp. 274-277.
[62] M. Krishnaveni and S. Mirunalini, “Therapeutic Potential of Phyllanthus emblica (amla): The Ayurvedic Wonder,” Journal of Basic and Clinical Physiology and Pharmacology, Vol. 21, No. 1, 2010, pp. 93-105.
[63] L. Pari and S. Venkateswaran, “Protective Role of Phaseolus vulgaris on Changes in the Fatty Acid Composition in Experimental Diabetes,” Journal of Medicinal Food, Vol. 7, No. 2, 2004, pp. 204-209.
http://dx.doi.org/10.1089/1096620041224120

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.